FUNCTION OF CALCITONIN RECEPTORS

降钙素受体的功能

基本信息

  • 批准号:
    6100313
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-01-01 至 1998-12-31
  • 项目状态:
    已结题

项目摘要

The recent cloning of porcine, human and murine calcitonin receptors (CTRs) by our laboratory and analysis of their structural features indicates that they belong to a new family of G protein-coupled receptors that includes the receptors for several members of the secretin/glucagon peptide family and parathyroid hormone/parathyroid hormone related peptide. The CTR cDNAs have provided us with experimental tools to define the molecular basis for the broad spectrum of biological and pharmacological effects of calcitonin (CT) and for determining the mechanisms underlying the observed cross-reactivity of CT with related ligands. The basis for the unique functional properties of the CTR, including the capacity to couple to multiple signal transduction pathways and to produce sustained activation of adenylate cyclase can also be explored. Initial studies indicate the presence of CTR isoforms and possibly subtypes with distinct functional properties. These findings provide the basis for Specific Aim 1 which is to clone and characterize the structural and functional properties of different CTR isoforms and related receptors. The observed structural and functional heterogeneity that we have detected among the CTR cDNAs that we have already cloned could proved the basis for tissue-specific regulation of responses to CT and related peptides. Specific Aim 2 will use in situ hybridization with probes prepared from the CTR clones and immunohistochemistry with antibodies to the CTR, to establish the tissue distribution of these receptors. Because the CTR family of receptors exhibits structural features that are different from the other members of the G protein- coupled receptor super family, the structure/function relationships for these additional clone CTR cDNAs, to define the structural determinants underlying the unique functional properties of the CTR. Specific Aim 3 proposes to use techniques of site-directed mutagenesis and construction of chimeric receptors to define the structural domains associated with ligand binding and coupling to G proteins associated with activation of specific signaling pathways. The development of refractoriness ("escape") to the hypocalcemic effects of CT is a significant problem in the clinical and therapeutic use of CT. Insights into the mechanisms underlying this condition should lead to more effective use of CT in the treatment of disorders of skeletal remodeling. The goal of Specific Aim 4 will be to define the molecular and cellular basis of this state of refractoriness to CT and to establish its relationship to the processes of receptor desensitization and down-regulation.
猪、人和小鼠降钙素受体的克隆 (CTRS)及其结构特征分析 表明它们属于一个新的G蛋白偶联受体家族 这包括几个促胰液素/高血糖素的受体。 肽家族与甲状旁腺激素/甲状旁腺激素相关 多肽。CTR cDNA为我们提供了实验工具 定义广谱的生物和生物的分子基础 降钙素(CT)的药理作用及测定 观察到CT与相关基因交叉反应的机制 配基。CTR独特的功能特性的基础, 包括连接到多个信号转导通路的能力 而产生持续激活的腺苷酸环化酶也可以 探索过了。初步研究表明,CTR亚型和 可能是具有不同功能属性的子类型。这些发现 为具体目标1提供基础,即克隆和表征 不同CTR亚型和不同亚型的结构和功能特性 相关受体。观察到的结构和功能的异质性 我们在已经克隆的CTR cDNA中检测到 可以证明对CT反应的组织特异性调节的基础 以及相关的多肽。特定目标2将使用原位杂交技术 从CTR克隆制备的探针和免疫组织化学 CTR抗体,以确定这些抗体的组织分布 感受器。因为CTR受体家族表现出结构 与G蛋白的其他成员不同的特征- 偶联受体超家族的结构/功能关系 这些额外的克隆CTR cDNA,以定义结构决定因素 这是CTR独特的功能特性的基础。具体目标3 建议使用定点突变和构建技术 以定义与之相关的结构域 与激活相关的G蛋白的配体结合和偶联 特定的信号通路。耐火性的发展 (“逃避”)CT的低血钙效应是一个重要的问题 CT的临床和治疗应用。对机制的洞察 潜在的这种情况应该导致更有效地使用CT在 治疗骨骼重塑障碍。明确目标的目标 4将定义这种状态的分子和细胞基础 对CT的耐受性及其与过程的关系 受体脱敏和下调。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEVEN GOLDRING其他文献

STEVEN GOLDRING的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEVEN GOLDRING', 18)}}的其他基金

ProGel Technology for Better Management of Osteoarthritis Pain
ProGel 技术可更好地治疗骨关节炎疼痛
  • 批准号:
    10326409
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
ProGel Technology for Better Management of Osteoarthritis Pain
ProGel 技术可更好地治疗骨关节炎疼痛
  • 批准号:
    10013068
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
ProGel Technology for Better Management of Osteoarthritis Pain
ProGel 技术可更好地治疗骨关节炎疼痛
  • 批准号:
    10281291
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
CELLULAR RESPONSES TO INORGANIC PARTICULATES
细胞对无机颗粒的反应
  • 批准号:
    6375146
  • 财政年份:
    1999
  • 资助金额:
    --
  • 项目类别:
CELLULAR RESPONSES TO INORGANIC PARTICULATES
细胞对无机颗粒的反应
  • 批准号:
    6511933
  • 财政年份:
    1999
  • 资助金额:
    --
  • 项目类别:
CELLULAR RESPONSES TO INORGANIC PARTICULATES
细胞对无机颗粒的反应
  • 批准号:
    6171148
  • 财政年份:
    1999
  • 资助金额:
    --
  • 项目类别:
CELLULAR RESPONSES TO INORGANIC PARTICULATES
细胞对无机颗粒的反应
  • 批准号:
    6607019
  • 财政年份:
    1999
  • 资助金额:
    --
  • 项目类别:
CELLULAR RESPONSES TO INORGANIC PARTICULATES
细胞对无机颗粒的反应
  • 批准号:
    2904798
  • 财政年份:
    1999
  • 资助金额:
    --
  • 项目类别:
CALCITONIN RECEPTORS IN DEVELOPMENT
降钙素受体的发育
  • 批准号:
    6100314
  • 财政年份:
    1997
  • 资助金额:
    --
  • 项目类别:
GORDON CONFERENCE ON CELL AND MOLECULAR BIOLOGY OF BONES
骨骼细胞和分子生物学戈登会议
  • 批准号:
    2083284
  • 财政年份:
    1995
  • 资助金额:
    --
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目

相似海外基金

Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
  • 批准号:
    MR/Y009681/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Preclinical development of an extracellular vesicle biotherapeutic for juvenile idiopathic arthritis
幼年特发性关节炎细胞外囊泡生物治疗药物的临床前开发
  • 批准号:
    10068495
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Collaborative R&D
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Exploring the inflammatory mediators degraded by MMP-2 in MMP-2-deficient mice with knee arthritis through a novel TMT-TAILS quantitative proteomics
通过新型 TMT-TAILS 定量蛋白质组学探索 MMP-2 缺陷型膝关节炎小鼠中 MMP-2 降解的炎症介质
  • 批准号:
    24K19850
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
  • 批准号:
    491810
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
The role of diet, as mediated by the gut microbiome, on childhood arthritis disease activity: a feasibility intervention study.
肠道微生物组介导的饮食对儿童关节炎疾病活动的作用:一项可行性干预研究。
  • 批准号:
    489316
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
Investigation of hypoxia-inducible factor-1 (HIF-1) as a novel therapeutic target for juvenile idiopathic arthritis.
研究缺氧诱导因子-1 (HIF-1) 作为幼年特发性关节炎的新治疗靶点。
  • 批准号:
    23K14987
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
  • 批准号:
    EP/Y027760/1
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Fellowship
The roles and mechanisms of inflammation resolution in the development of Rheumatoid Arthritis
炎症消退在类风湿关节炎发展中的作用和机制
  • 批准号:
    10733789
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了